Clinical Efficacy in TBI
The effects of Cerebrolysin® were evaluated with various clinical outcome scales during acute and post-acute TBI phases.
Studies showed the following key benefits of Cerebrolysin®:
Studies showed the following key benefits of Cerebrolysin®:
Cerebrolysin® is safe and well tolerated.
Effective treatment after TBI
Muresanu et al. 2020 showed significant effect size of Cerebrolysin® in the multidimensional outcome ensemble. In all 13 single outcome scales Cerebrolysin® was superior to placebo and 6 outcome measurements demonstrated stand-alone statistical significance.
Saves lives
A reduction of the mortality rate was shown in the meta-analysis of Vester et al. 2021 , as 8.4% of patients died in the placebo group vs. only 3.9% in the Cerebrolysin® group.
Early recovery
As early as on day 10, CAPTAIN 2 (Muresanu et al. 2020 ) showed superiority of Cerebrolysin® versus placebo overall (MW = 0.54) and in 6 out of 7 single outcome scales. on day 30, the effect size increased to MW = 0.576. So already one early treatment cycle brings medium superiority on day 30.
Better quality of life
The CAPTAIN meta-analysis (Vester et al. 2021) found normalization of the HADS score (Score 0-7 at Day 90) in 70.5% of patients treated with Cerebrolysin® as compared to 39.5% of patients in the placebo group. The rate difference of 31% is a substantial reduction of depression.
Improvement of memory
and concentration
The most common neurocognitive consequences of TBI at all levels of severity are disturbances of memory, attention and executive functioning. The CAPTAIN 2 study (Muresanu et al., 2020) investigated exactly these important domains with the following assessment tools:
- Digit span backward test
- Processing speed index and
- Stroop word/dots test.
The study showed large-sized, significant improvements in these three assessments.
Double-click this headline to edit the text.
Muresanu, Dafin f., et al. „Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIn II trial.“ neurological Sciences 41.5 (2020): 1171-1181.
Vester, Johannes C., et al. „Cerebrolysin® after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIn trial series.“ neurological Sciences (2021): 1-11.
Vester, Johannes C., et al. „Cerebrolysin® after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIn trial series.“ neurological Sciences (2021): 1-11.